Literature DB >> 11435458

Reversal of established autoimmune diabetes by restoration of endogenous beta cell function.

S Ryu1, S Kodama, K Ryu, D A Schoenfeld, D L Faustman.   

Abstract

In NOD (nonobese diabetic) mice, a model of autoimmune diabetes, various immunomodulatory interventions prevent progression to diabetes. However, after hyperglycemia is established, such interventions rarely alter the course of disease or allow sustained engraftment of islet transplants. A proteasome defect in lymphoid cells of NOD mice impairs the presentation of self antigens and increases the susceptibility of these cells to TNF-alpha-induced apoptosis. Here, we examine the hypothesis that induction of TNF-alpha expression combined with reeducation of newly emerging T cells with self antigens can interrupt autoimmunity. Hyperglycemic NOD mice were treated with CFA to induce TNF-alpha expression and were exposed to functional complexes of MHC class I molecules and antigenic peptides either by repeated injection of MHC class I matched splenocytes or by transplantation of islets from nonautoimmune donors. Hyperglycemia was controlled in animals injected with splenocytes by administration of insulin or, more effectively, by implantation of encapsulated islets. These interventions reversed the established beta cell-directed autoimmunity and restored endogenous pancreatic islet function to such an extent that normoglycemia was maintained in up to 75% of animals after discontinuation of treatment and removal of islet transplants. A therapy aimed at the selective elimination of autoreactive cells and the reeducation of T cells, when combined with control of glycemia, is thus able to effect an apparent cure of established type 1 diabetes in the NOD mouse.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11435458      PMCID: PMC209340          DOI: 10.1172/JCI12335

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

1.  Inactivation of misselected CD8 T cells by CD8 gene methylation and cell death.

Authors:  G A Pestano; Y Zhou; L A Trimble; J Daley; G F Weber; H Cantor
Journal:  Science       Date:  1999-05-14       Impact factor: 47.728

2.  Long-term T cell memory requires the surface expression of self-peptide/major histocompatibility complex molecules.

Authors:  M A Markiewicz; C Girao; J T Opferman; J Sun; Q Hu; A A Agulnik; C E Bishop; C B Thompson; P G Ashton-Rickardt
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

3.  NF-kappa B p105 processing via the ubiquitin-proteasome pathway.

Authors:  C Sears; J Olesen; D Rubin; D Finley; T Maniatis
Journal:  J Biol Chem       Date:  1998-01-16       Impact factor: 5.157

4.  Dissociation and exchange of the beta 2-microglobulin subunit of HLA-A and HLA-B antigens.

Authors:  F Hyafil; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

5.  Suppression of TNF-alpha-induced apoptosis by NF-kappaB.

Authors:  D J Van Antwerp; S J Martin; T Kafri; D R Green; I M Verma
Journal:  Science       Date:  1996-11-01       Impact factor: 47.728

6.  Transplantation of encapsulated canine islets into spontaneously diabetic BB/Wor rats without immunosuppression.

Authors:  R P Lanza; K M Borland; J E Staruk; M C Appel; B A Solomon; W L Chick
Journal:  Endocrinology       Date:  1992-08       Impact factor: 4.736

7.  BCG immunotherapy prevents recurrence of diabetes in islet grafts transplanted into spontaneously diabetic NOD mice.

Authors:  J R Lakey; B Singh; G L Warnock; R V Rajotte
Journal:  Transplantation       Date:  1994-04-27       Impact factor: 4.939

8.  Linkage of faulty major histocompatibility complex class I to autoimmune diabetes.

Authors:  D Faustman; X P Li; H Y Lin; Y E Fu; G Eisenbarth; J Avruch; J Guo
Journal:  Science       Date:  1991-12-20       Impact factor: 47.728

9.  Reduced expression of peptide-loaded HLA class I molecules on multiple sclerosis lymphocytes.

Authors:  F Li; M J Linan; M C Stein; D L Faustman
Journal:  Ann Neurol       Date:  1995-08       Impact factor: 10.422

10.  Murine pancreatic beta-cells express H-2K and H-2D but not Ia antigens.

Authors:  D Faustman; V Hauptfeld; J M Davie; P E Lacy; D C Shreffler
Journal:  J Exp Med       Date:  1980-06-01       Impact factor: 14.307

View more
  52 in total

1.  Immunomodulatory therapy of human type 1 diabetes: lessons from the mouse.

Authors:  J P Palmer
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 2.  Latent autoimmune diabetes in adults (LADA).

Authors:  Ramachandra G Naik; Jerry P Palmer
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

3.  Bone marrow cells are a source of undifferentiated cells to prevent Sjögren's syndrome and to preserve salivary glands function in the non-obese diabetic mice.

Authors:  Saeed Khalili; Younan Liu; Yoshinori Sumita; Ola M Maria; David Blank; Sharon Key; Eva Mezey; Simon D Tran
Journal:  Int J Biochem Cell Biol       Date:  2010-08-21       Impact factor: 5.085

4.  Adjuvant immunotherapy of experimental autoimmune encephalomyelitis: immature myeloid cells expressing CXCL10 and CXCL16 attract CXCR3+CXCR6+ and myelin-specific T cells to the draining lymph nodes rather than the central nervous system.

Authors:  Richard A O'Connor; Xujian Li; Seth Blumerman; Stephen M Anderton; Randolph J Noelle; Dyana K Dalton
Journal:  J Immunol       Date:  2012-01-27       Impact factor: 5.422

Review 5.  Cellular therapies for type 1 diabetes.

Authors:  D D Lee; E Grossman; A S Chong
Journal:  Horm Metab Res       Date:  2008-02       Impact factor: 2.936

6.  Reversal of Sjogren's-like syndrome in non-obese diabetic mice.

Authors:  Simon D Tran; Shohta Kodama; Beatrijs M Lodde; Ildiko Szalayova; Sharon Key; Saeed Khalili; Denise L Faustman; Eva Mezey
Journal:  Ann Rheum Dis       Date:  2006-12-19       Impact factor: 19.103

Review 7.  The primacy of CD8 T lymphocytes in type 1 diabetes and implications for therapies.

Authors:  Denise L Faustman; Miriam Davis
Journal:  J Mol Med (Berl)       Date:  2009-08-21       Impact factor: 4.599

8.  The novel inosine analogue, INO-2002, protects against diabetes development in multiple low-dose streptozotocin and non-obese diabetic mouse models of type I diabetes.

Authors:  Jon G Mabley; Pal Pacher; Kanneganti G K Murthy; William Williams; Garry J Southan; Andrew L Salzman; Csaba Szabo
Journal:  J Endocrinol       Date:  2008-06-18       Impact factor: 4.286

Review 9.  Adipose stem cell-based regenerative medicine for reversal of diabetic hyperglycemia.

Authors:  Hyun Joon Paek; Courtney Kim; Stuart K Williams
Journal:  World J Diabetes       Date:  2014-06-15

10.  Inosine protects against the development of diabetes in multiple-low-dose streptozotocin and nonobese diabetic mouse models of type 1 diabetes.

Authors:  Jon G Mabley; Alex Rabinovitch; Wilma Suarez-Pinzon; György Haskó; Pál Pacher; Robert Power; Gary Southan; Andrew Salzman; Csaba Szabó
Journal:  Mol Med       Date:  2003 Mar-Apr       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.